
|Articles|November 15, 2003
AMO sharpens focus on innovative technology
Author(s)Mark L. Dlugoss
A sign of an excellent company is one that capitalizes on its strengths, minimizes its weaknesses, takes advantage of its opportunities, and recognizes its threats, according to James V. Mazzo, president and chief executive officer of Advanced Medical Optics (AMO).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
3
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
4
PRIMA retinal implant restores vision in patients with advanced GA
5














































